Compare AstraZeneca plc (AZN) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Extra Space Storage, Inc. — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while Extra Space Storage, Inc. trades at $145.35 (market cap $30.74B). The key difference: AstraZeneca plc is far larger — about 8.2× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.45%). Which is the better fit depends on your goals.
| AZN | EXR | |
|---|---|---|
Market Cap | $253.13B | $30.74B |
Sector | Health | Real Estate |
52-Week High | $209.48 | $152.75 |
52-Week Low | $137.44 | $126.67 |
Enterprise Value | $279.37B | $44.54B |
Dividend Yield | 1.92% | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
EXR trades at $145.32, up 0.94% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating estimates at $1.14 versus $1.12 expected, maintaining a three-quarter beat streak. Revenue grew to $3.38B in 2025 with robust 70.63% gross margins. Analyst consensus is mixed with 12 Buy and 16 Hold ratings, targeting $155.88 average price. Recent $550 million debt issuance supports expansion amid steady operational cash flow of $1.85B.
Outlook remains stable with resilient self-storage demand offset by debt concerns. The 6.92% ROE and 32.66 P/E suggest fair valuation. Key risks include rising expenses and competitive supply pressures. Institutional sentiment leans cautious despite consistent dividend payments, with technical resistance near $146 limiting near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
